The stock of Crispr Therapeutics AG (NASDAQ:CRSP) closed at $51.18 losing 1.14% in yesterday’s trading session. This company has today moved ahead to make the pronouncement regarding the new data presentation from its allogeneic chimeric antigen receptor T cell (CAR-T) program.
This happened way back in 2018 at the American Association for Cancer Research (AACR) Annual Meeting and the expectations were high among the concerned parties. One notable aspect about the data that was unleashed today was that it was a clear demonstration of the generation of CAR-T cells targeted to CD70 and BCMA through CRISPR/Cas9 gene editing which are associated with potent cell killing, consistent expression and above all high editing rates.
The Head of R&D, CRISPR Therapeutics Tony Ho in one of his interviews had quite much to say regarding the latest developments. He spoke specifically regarding the studies presented today outlining that they had used the multiplexed CRISPR gene editing. That was specifically towards the overall modification of the healthy donor T cells in coming up with the CAR-T cells which potentially and selectively targeted the tumor antigen of choice.
Her delved deeper into the matter to outline that the data that was presented served as further evidence that indeed the CRISPR/Cas9 could be moving quite a long way helping with the manufacture of the ext-generation CAR-T cell therapies.
Another official well conversant with the matter proceeded to state that it would be helping the broader population of patients and of course that would be including those that have been struggling for over quite some time with the solid tumors.
The company’s CEO in a recent board meeting outlined that as a company they were doing everything they could towards ensuring that they witnessed immense success in line with addressing the need for durable and effective therapies for both hematologic and solid tumors.
According to him, the CRISPR/Cas9 genome editing was a step towards the right direction more so considering that it was what generated the allogeneic CAR-T cells which targeted the CD70 antigen. The long and short of it is that much is happening at the moment in line with pushing for better healthcare for patients around the globe.